SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Jounce Therapeutics Inc. (JNCE)

JNCE RSS Feed
Add JNCE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/11/2017 1:49:16 PM - Followers: 1 - Board type: Free - Posts Today: 0

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
JNCE
Current Price
Volume:
Bid Ask Day's Range
JNCE News: Current Report Filing (8-k) 05/23/2017 11:58:51 AM
JNCE News: Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual M... 05/17/2017 05:00:00 PM
JNCE News: Quarterly Report (10-q) 05/09/2017 01:51:24 PM
JNCE News: Current Report Filing (8-k) 05/09/2017 08:35:30 AM
JNCE News: Jounce Therapeutics Reports First Quarter 2017 Financial Results 05/09/2017 08:00:00 AM
News News Alert: Current Report Filing (8-k) 05/23/2017 11:58:51 AM
PostSubject
#1   JNCE bullish 24.61 stocktrademan 05/11/17 01:49:16 PM
PostSubject